Table 1.
Clinical outcome of macaques infected intravaginally with R5 SHIV SF162P3N
| Clinical status | Animal | Challenge dose; frequency | Time to necropsy (weeks) | |
|---|---|---|---|---|
| Transient Viremic |
AH94 |
10,000; 2X |
54 |
|
| |
DE37 |
10,000; 2X |
59 |
|
| Chronic progressor |
CG45 |
1,000; 1X |
59 |
|
| CG63 |
1,000; 1X |
59 |
||
| FR25 |
10,000; 1X |
129 |
||
| FV44 |
10,000; 1X |
53 |
||
| GH62 |
10,000; 1X |
53 |
||
| GR56 |
10,000; 1X |
53 |
||
| CF18 |
10,000; 2X |
52* |
||
| FH84 |
10,000; 2X |
104* |
||
| Rapid progressor |
DG17 |
1,000; 1X |
22* |
|
| |
GC70 |
1,000; 1X |
24* |
|
| |
EI77 |
10,000; 1X |
27* |
|
| EL48 | 10,000; 1X | 17* |
*AIDS-related euthanasia.